A Pilot Study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)
Phase of Trial: Phase I
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Drug hypersensitivity
- Focus Therapeutic Use
- 28 May 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Interim results (n=9) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 25 Oct 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2018.